Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Answers to Questions on Contemporary Management of Hemophilia A

In this podcast episode, listen to Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, as they answer questions from a clinician audience on new and established approaches for managing hemophilia A in pediatric and adult patients.
Michael Callaghan, MD
Miguel A. Escobar, MD
person default
Rebecca Kruse-Jarres, MD, MPH
Released: February 4, 2021

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:

  • Maintaining long-term musculoskeletal health
  • Identifying patients most likely to benefit from pharmacokinetics-guided prophylaxis
  • Managing combination therapies in older patients with comorbidities
  • Youngest age at which patients can be considered for emicizumab
  • Development of resistance to emicizumab
  • Switching recombinant factor therapies
  • Using bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitors
  • Potential clinical role of extending FVIII half-life with BIVV001
  • Considerations when dosing emicizumab monthly

Presenters:

Michael Callaghan, MD
Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Children’s Hospital of Michigan
Detroit, Michigan

Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Rebecca Kruse-Jarres, MD, MPH
Professor
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Sanofi Genzyme Corporation
Takeda Pharmaceutical Company Ltd

Related Content

Download this short slideset from Clinical Care Options (CCO) on the management of newly diagnosed and relapsed light-chain (AL) amyloidosis

Ankit Kansagra, MD Shaji K. Kumar, MD Vaishali Sanchorawala, MD Released: January 19, 2022

Downloadable PDF summary transcript of expert answers to questions on hemophilia A management, from Clinical Care Options (CCO)

Miguel A. Escobar, MD Mark Reding, MD Guy A. Young, MD Released: January 18, 2022

Podcast with expert insight on the use of current and emerging treatments for patients with hemophilia A, from Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Mark Reding, MD Guy A. Young, MD
Released: January 14, 2022

Downloadable summary slideset from a live ASH 2021 satellite symposium on optimizing outcomes in hemophilia A with factor and nonfactor therapy from Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Mark Reding, MD Guy A. Young, MD
Released: December 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings